(MIRM) Mirum Pharmaceuticals - NASDAQ

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 5.701m USD | Total Return: 105.4% in 12m

Bile Acid Inhibitors, Rare Disease Therapies, Liver Medications
Total Rating 34
Safety 34
Buy Signal -0.28
Biotechnology
Industry Rotation: -7.2
Market Cap: 5.70B
Avg Turnover: 64.8M
Risk 3d forecast
Volatility52.8%
VaR 5th Pctl8.61%
VaR vs Median-0.97%
Reward TTM
Sharpe Ratio1.75
Rel. Str. IBD87.2
Rel. Str. Peer Group67.3
Character TTM
Beta1.105
Beta Downside0.583
Hurst Exponent0.478
Drawdowns 3y
Max DD32.52%
CAGR/Max DD1.63
CAGR/Mean DD4.94
EPS (Earnings per Share) EPS (Earnings per Share) of MIRM over the last years for every Quarter: "2021-06": -1.45, "2021-09": -1.6, "2021-12": -1.66, "2022-03": -1.17, "2022-06": -0.84, "2022-09": -1.02, "2022-12": -0.99, "2023-03": -0.8, "2023-06": -0.65, "2023-09": -0.57, "2023-12": -0.66, "2024-03": -0.54, "2024-06": -0.52, "2024-09": -0.3, "2024-12": -0.49, "2025-03": -0.3, "2025-06": -0.12, "2025-09": 0.05, "2025-12": -0.12, "2026-03": -1.08,
Last SUE: -3.97
Qual. Beats: -1
Revenue Revenue of MIRM over the last years for every Quarter: 2021-06: 11, 2021-09: 5, 2021-12: 3.138, 2022-03: 12.892, 2022-06: 17.484, 2022-09: 18.78, 2022-12: 27.906, 2023-03: 31.598, 2023-06: 37.497, 2023-09: 47.725, 2023-12: 69.554, 2024-03: 69.222, 2024-06: 77.875, 2024-09: 90.377, 2024-12: 99.414, 2025-03: 111.585, 2025-06: 127.785, 2025-09: 133.01, 2025-12: 148.932, 2026-03: 159.882,
Rev. CAGR: 74.94%
Rev. Trend: 98.5%
Last SUE: 1.00
Qual. Beats: 1

Warnings

Share dilution 20.4% YoY

Interest Coverage Ratio -4.4 is critical

Altman Z'' -3.30 < 1.0 - financial distress zone

Below Avwap Earnings

Tailwinds

No distinct edge detected

Description: MIRM Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of therapies for rare and orphan diseases, particularly those affecting the liver and metabolic systems. Its primary product, LIVMARLI (maralixibat), is an orally administered ileal bile acid transporter (IBAT) inhibitor approved for treating cholestatic pruritus in Alagille syndrome patients. The company’s commercial portfolio also includes Cholbam for bile acid synthesis disorders and Chenodal for gallbladder stones and cerebrotendinous xanthomatosis.

The orphan drug sector often benefits from regulatory incentives such as extended market exclusivity and smaller clinical trial requirements due to the limited patient populations served. Mirum utilizes a business model centered on strategic licensing and asset acquisitions from established pharmaceutical entities like Pfizer and Sanofi to build its pipeline. Current research and development efforts focus on Volixibat for cholestatic liver diseases and Brelovitug for chronic HDV infection.

For more detailed insights into the companys fundamentals, you may want to explore the data available on ValueRay. Headquartered in Foster City, California, the company maintains multiple collaborative agreements to support its manufacturing and clinical trial infrastructure.

Headlines to Watch Out For
  • LIVMARLI market penetration in Alagille syndrome drives core quarterly revenue growth
  • Label expansion for LIVMARLI in cholestatic pruritus increases total addressable market
  • Volixibat clinical trial data readouts determine long-term pipeline valuation and sentiment
  • Integration of acquired Travere bile acid assets impacts operational margin efficiency
  • Regulatory approval timelines for Chenodal in cerebrotendinous xanthomatosis influence future earnings guidance
Piotroski VR-10 (Strict) 2.5
Net Income: -798.8m TTM > 0 and > 6% of Revenue
FCF/TA: -0.19 > 0.02 and ΔFCF/TA -15.33 > 1.0
NWC/Revenue: 52.07% < 20% (prev 74.68%; Δ -22.61% < -1%)
CFO/TA -0.19 > 3% & CFO -171.0m > Net Income -798.8m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.09 > 1.5 & < 3
Outstanding Shares: last quarter (58.9m) vs 12m ago 20.38% < -2%
Gross Margin: 81.36% > 18% (prev 77.10%; Δ 4.26% > 0.5%)
Asset Turnover: 72.05% > 50% (prev 54.94%; Δ 17.11% > 0%)
Interest Coverage Ratio: -4.40 > 6 (EBIT TTM -63.4m / Interest Expense TTM 14.4m)
Altman Z'' -3.30
A: 0.33 (Total Current Assets 569.4m - Total Current Liabilities 272.8m) / Total Assets 890.9m
B: -1.64 (Retained Earnings -1.46b / Total Assets 890.9m)
C: -0.08 (EBIT TTM -63.4m / Avg Total Assets 790.6m)
D: 0.37 (Book Value of Equity 242.5m / Total Liabilities 648.4m)
Altman-Z'' = -3.30 = D
Beneish M -2.92
DSRI: 0.92 (Receivables 133.1m/95.9m, Revenue 569.6m/379.3m)
GMI: 0.95 (GM 77.10% / 81.36%)
AQI: 0.88 (AQ_t 0.34 / AQ_t-1 0.39)
SGI: 1.50 (Revenue 569.6m / 379.3m)
TATA: -0.70 (NI -798.8m - CFO -171.0m) / TA 890.9m)
Beneish M = -2.92 (Cap -4..+1) = A
What is the price of MIRM shares?

As of June 12, 2026, the stock is trading at USD 99.54 with a total of 687,763 shares traded.
Over the past week, the price has changed by +7.62%, over one month by -6.24%, over three months by +8.49% and over the past year by +105.41%.

Is MIRM a buy, sell or hold?

Mirum Pharmaceuticals has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy MIRM.

  • StrongBuy: 6
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the MIRM price?
Analysts Target Price 144.2 44.9%
Mirum Pharmaceuticals (MIRM) - Fundamental Data Overview as of 08 June 2026
Market Cap USD = 5.70b (5.70b USD * 1.0 USD.USD)
P/E Forward = 2000.0
P/S = 10.0078
P/B = 23.2439
Revenue TTM = 569.6m USD
EBIT TTM = -63.4m USD
EBITDA TTM = -38.3m USD
Long Term Debt = 310.3m USD (from longTermDebt, last quarter)
Short Term Debt = 2.35m USD (from shortTermDebt, last quarter)
Debt = 337.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 13.5m
Net Debt = -49.0m USD (calculated: Debt 337.3m - CCE 386.3m)
Enterprise Value = 5.65b USD (5.70b + Debt 337.3m - CCE 386.3m)
Interest Coverage Ratio = -4.40 (Ebit TTM -63.4m / Interest Expense TTM 14.4m)
EV/FCF = -32.75x (Enterprise Value 5.65b / FCF TTM -172.6m)
FCF Yield = -3.05% (FCF TTM -172.6m / Enterprise Value 5.65b)
FCF Margin = -30.29% (FCF TTM -172.6m / Revenue TTM 569.6m)
Net Margin = -140.2% (Net Income TTM -798.8m / Revenue TTM 569.6m)
Gross Margin = 81.36% ((Revenue TTM 569.6m - Cost of Revenue TTM 106.2m) / Revenue TTM)
Gross Margin QoQ = 81.94% (prev 80.97%)
Tobins Q-Ratio = 6.34 (Enterprise Value 5.65b / Total Assets 890.9m)
Interest Expense / Debt = 4.27% (Interest Expense 14.4m / Debt 337.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -50.1m (EBIT -63.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.09 (Total Current Assets 569.4m / Total Current Liabilities 272.8m)
Debt / Equity = 1.39 (Debt 337.3m / totalStockholderEquity, last quarter 242.5m)
 Debt / EBITDA = 1.28 (negative EBITDA) (Net Debt -49.0m / EBITDA -38.3m)
 Debt / FCF = 0.28 (negative FCF - burning cash) (Net Debt -49.0m / FCF TTM -172.6m)
 Total Stockholder Equity = 276.1m (last 4 quarters mean from totalStockholderEquity)
 RoA = -101.0% (out of range, set to none)
 RoE = -289.3% (Net Income TTM -798.8m / Total Stockholder Equity 276.1m)
RoCE = -10.81% (EBIT -63.4m / Capital Employed (Equity 276.1m + L.T.Debt 310.3m))
 RoIC = -8.46% (negative operating profit) (NOPAT -50.1m / Invested Capital 592.0m)
 WACC = 9.51% (E(5.70b)/V(6.04b) * Re(9.87%) + D(337.3m)/V(6.04b) * Rd(4.27%) * (1-Tc(0.21)))
Discount Rate = 9.87% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 10.80%
 [DCF] Fair Price = unknown (Cash Flow -172.6m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -3.97 | # QB: -1
Revenue Correlation: 98.50 | Revenue CAGR: 74.94% | SUE: 1.00 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.81 | Chg30d=-87.79% | Revisions=-20% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.70 | Chg30d=-58.11% | Revisions=-33% | Analysts=4
EPS current Year (2026-12-31): EPS=-16.33 | Chg30d=-902.70% | Revisions=-20% | GrowthEPS=-3374.5% | GrowthRev=+29.5%
EPS next Year (2027-12-31): EPS=-0.56 | Chg30d=N/A | Revisions=+0% | GrowthEPS=+96.6% | GrowthRev=+20.4%
[Analyst] Revisions Ratio: -33%